A roadmap for driving CAR T cells toward the oncogenic immunopeptidome.
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
10 01 2022
10 01 2022
Historique:
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
19
2
2022
Statut:
ppublish
Résumé
A critical barrier to CAR T cell therapy is the paucity of target antigens that are broadly and stably expressed exclusively in tumors. In their comprehensive multi-omics and pre-clinical study, Yarmarkovich et al. provide proof of principle for the development and efficacy of peptide centric (PC)-CARs targeting the oncogenic immunopeptidome of neuroblastoma.
Identifiants
pubmed: 35016027
pii: S1535-6108(21)00664-4
doi: 10.1016/j.ccell.2021.12.011
pii:
doi:
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
20-22Commentaires et corrections
Type : CommentOn
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests V.Z. is a consultant for Cellestia Biotech. G.C. has received grants or research support or is coinvestigator in clinical trials by Bristol-Myers-Squibb, Celgene, Boehringer Ingelheim, Roche, Tigen Pharma, Iovance, and Kite. The institution of G.C. (CHUV) has received honoraria for consultations or presentations by G.C. from Roche, Genentech, BMS, AstraZeneca, Sanofi-Aventis, Nextcure, and GeneosTx. G.C. has patents in the domain of antibodies and vaccines targeting the tumor vasculature as well as technologies related to T cell expansion and engineering for T cell therapy. G.C. receives royalties from the University of Pennsylvania.